Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-Aventis in malaria partnership

Sanofi-Aventis in malaria partnership

24th April 2008

Sanofi-Aventis has confirmed a new partnership with the Drugs for Neglected Diseases initiative (DNDi) for the co-development of a new pharmaceutical product to tackle malaria.

The new product, ASAQ, is a fixed-dose combination of artesunate and amodiaquine.

Francois Bompart, vice-president, medical and head of the Impact Malaria Programme at Sanofi-Aventis, said: “Drugs alone are not enough. We also need to ensure that the medical profession and populations have access to information on the drugs and the diseases they treat.”

Therefore, the firm provides a number of other resources alongside the drug to ensure that medical professionals know how to use the drug and that the populations of countries where ASAQ is used are fully aware of malaria and its dangers.

Work with the National Malaria Control Programmes is also carried out to ensure that people are aware of the disease.

Malaria affects a number of countries across different continents. Africa, Latin America and parts of Asia are all home to the disease.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.